SS&C Announces $1 Billion Common Stock Repurchase ProgramSS&C announced that as part of the Company's capital allocation strategy to maximize stockholder value, its Board of Directors ("Board") has authorized the
Bristol Myers Squibb & Co (NYSE: BMY) said that its Q2 revenues of $11.23 billion declined 6% Y/Y, or 5% when adjusted for foreign exchange, due to lower sales of Revlimid, partially offset by in-line products and our new product portfolio.